Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hyperthermia Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

IEEM- Work:Rest Cycles in Burn Survivors- Humidity

NCT06966336
View directory record Official record
Conditions
Hyperthermia, Burn Injury
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Heat Pads and Foam Rolling on Strength in Athletes.

NCT07569601
View directory record Official record
Conditions
Healthy Participants
Interventions
Heating Pad, Foam Roller
Device
Lead sponsor
University of Redlands
Other
Eligibility
18 Years to 23 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Redlands, California
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting No phase listed Observational

Thermodynamic Model of Hyperthermia in Humans Undergoing HIPEC

NCT05426928
View directory record Official record
Conditions
HIPEC
Interventions
Additional temperature monitoring/recording
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

West Nile Virus Natural History

NCT00138463
View directory record Official record
Conditions
West Nile Virus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2011 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed Phase 2 Interventional

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

NCT02349958
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer, Mesotheliomas, Gastrointestinal Cancers, Cervical Cancer
Interventions
HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0, HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
Device
Lead sponsor
Bay Area Gynecology Oncology
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

Heat thErapy And mobiLity in COVID-19 Survivors

NCT06928116
View directory record Official record
Conditions
Long COVID
Interventions
Heat therapy, Sham Control, Walking
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years to 90 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated

NCT00869713
View directory record Official record
Conditions
Rift Valley Fever
Interventions
Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

NCT00290147
View directory record Official record
Conditions
Dengue
Interventions
D1ME100 (dengue-1 premembrane/envelope DNA vaccine)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults

NCT02317900
View directory record Official record
Conditions
Dengue
Interventions
TV005, Placebo, rDEN2∆30-7169
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dengue 3 Human Infection Model (DENV-3)

NCT04298138
View directory record Official record
Conditions
Dengue
Interventions
Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Biological
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 45 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up

NCT02431923
View directory record Official record
Conditions
Ebola Virus Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 100 Years
Enrollment
4,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 2 Interventional

ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

NCT01815359
View directory record Official record
Conditions
Appendix Cancer, Colorectal Cancer
Interventions
Cytoreductive Surgery, HIPEC with Mitomycin-C, EPIC with FUDR and Leucovorin
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
9
States / cities
Miami, Florida • St Louis, Missouri • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed No phase listed Observational

Diagnosis and Characterization of Dengue Fever in Children

NCT00946218
View directory record Official record
Conditions
Dengue Fever
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 11 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 3 Interventional

To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405)

NCT00658918
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, Hay Fever
Interventions
Ciclesonide nasal, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 5 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine

NCT00473135
View directory record Official record
Conditions
Dengue
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Jul 21, 2026, 2:19 PM EDT
Not listed No phase listed Observational

ERAS® Guidelines Validation of CRS With or Without HIPEC

NCT05185791
View directory record Official record
Conditions
Peritoneal Diseases
Interventions
Pre-ERAS® phase (current clinical practice), Post-ERAS® implementation phase
Other
Lead sponsor
Hospices Civils de Lyon
Other
Eligibility
18 Years and older
Enrollment
288 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Jul 21, 2026, 2:19 PM EDT
Active, not recruiting Phase 1 Interventional

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

NCT01970722
View directory record Official record
Conditions
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IV Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Drug · Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
4
States / cities
Corona, California • Duarte, California • Upland, California + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

NCT00679172
View directory record Official record
Conditions
Typhoid
Interventions
Dose of 5.0 x 10^9 CFU (Cohort 1), Dose of 7.5 x 10^9 CFU (Cohort 2), Dose of 1.1 x 10^10 CFU (Cohort 3), Dose of of 1.7 x 10^10 CFU (Cohort 4), Placebo (Cohorts 1-4 pooled)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 50 Years
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
South Miami, Florida • Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

NCT00078195
View directory record Official record
Conditions
Hay Fever, Hypersensitivity, Allergy, Rhinitis
Interventions
omalizumab, Placebo omalizumab, Ragweed rush immunotherapy (RIT), Placebo rush immunotherapy (RIT), Ragweed immunotherapy (IT), Placebo immunotherapy (IT)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Iowa City, Iowa • Omaha, Nebraska • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Jul 21, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Heat Waves and the Elderly - Cooling Modalities

NCT05484739
View directory record Official record
Conditions
Aging, Hyperthermia
Interventions
Water Spray, Fan, Water Spray and Fan, Control
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

NCT04983901
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem, Piperacillin-Tazobactam, Vancomycin, Daptomycin, Linezolid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Video Discharge Instructions for Fever and ED Recidivism

NCT01655251
View directory record Official record
Conditions
Children Who Present to the ED With Minor Febrile Illnesses
Interventions
Intervention
Behavioral
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Weeks to 18 Years
Enrollment
273 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 21, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma

NCT00002973
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
melphalan, hyperthermia treatment
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 21, 2026, 2:19 PM EDT